Deloitte buys drug safety firm Intrasphere

Deloitte has acquired substantially all of the assets of Intrasphere Technologies, a global drug safety and regulatory consulting business, to blend life sciences and research, as well as development practice with drug safety consulting. Terms of the deal were not disclosed.

Headquartered in Jersey City, N.J., Intrasphere provides professional services to help life sciences companies improve product safety, signal intelligence, pharmacovigilance and regulatory information management capabilities.

The acquired assets include Intrasphere’s PharmaCM, software that enables life sciences companies to register clinical trial information on government-mandated registries through the use of functionality that allows for content management and reuse. The PharmaCM product will be provided as a service offering within Deloitte Managed Analytics, which is led by Richard Cohen, principal at Deloitte Consulting.

The combined company will offer technologies that focus on enabling enhanced signal intelligence and analytics through the planning, design and implementation of drug safety data warehouses, adverse event management applications, remote data capture tools and assembly of periodic reporting for regulatory agencies. As a result, this new business will tap into Deloitte’s enterprise risk, security and regulatory compliance services and additional business advisory services.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.